AR035580A1 - Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentos - Google Patents
Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentosInfo
- Publication number
- AR035580A1 AR035580A1 ARP010103900A ARP010103900A AR035580A1 AR 035580 A1 AR035580 A1 AR 035580A1 AR P010103900 A ARP010103900 A AR P010103900A AR P010103900 A ARP010103900 A AR P010103900A AR 035580 A1 AR035580 A1 AR 035580A1
- Authority
- AR
- Argentina
- Prior art keywords
- bond
- halo
- nr11r12
- aryl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
Abstract
Compuestos de fórmula (1) donde X es N o CH, n es 0 a 3; R1 es: (a)alquilo C1-6 de cadena lineal o ramificada, (b) alquenilo C1-6 de cadena lineal o ramificada, (c) alquinilo C1-6 de cadena lineal o ramificada, (d) heterociclo, (e) heterociclo aromático, (f) arilo, (g) hidrógeno; estando los citados grupos (a), (b) y (c) opcionalmente sustituidos adicionalmente con: cicloalquilo C3-7, arilo, heterociclo aromático, heterociclo, OR11, NR11R12, S(O)pR11, OC(O)R11, CO2R11, CONR11R12, SO2NR11R12, halo y NHSO2R11, pudiendo estar R1 unido en cualquier posición en el anillo de imidazol; R2 y R3 se seleccionan cada uno independientemente de hidrógeno, alquilo C1-6, opcionalmente sustituido adicionalmente con OR11, halo; o pudiendo estar R2 y R3 unidos para formar un enlace, siendo el citado enlace alquileno C2-6; R4 es hidrógeno, alquilo C1-6, opcionalmente sustituido adicionalmente con cicloalquilo C3-7, arilo, OR11, halo y R11; o pudiendo estar R4 y R10 unidos para formar un enlace, siendo dicho enlace alquileno C1-4, opcionalmente sustituido adicionalmente con OR11, halo y R11; R5 y R6 se seleccionan de: hidrógeno, arilo, alquilo C1-6, estando el citado alquilo opcionalmente sustituido adicionalmente con cicloalquilo C3-7, heterociclo aromático, heterociclo, arilo, OR11, R11 y halo; o pudiendo estar R10 y cualquiera de R5 y R6 unidos para formar un enlace, siendo el citado enlace un alquileno C1-3, opcionalmente sustituido adicionalmente con OR11, halo, R11 y arilo; o pudiendo estar R5 y R6 unidos para formar un enlace, siendo el citado enlace alquileno C2-6; R7 y R8 se seleccionan independientemente de: hidrógeno, alquilo C1-6 opcionalmente sustituido adicionalmente con OR11, halo, arilo y R11; o pudiendo estar R7 y R8 unidos para formar un enlace, siendo el citado enlace alquileno C2-6; R9 y R10 se seleccionan independientemente de: hidrógeno, C(NR11)NR11R12, alquilo C1-6, estando el citado alquilo opcionalmente sustituido con OR11, halo, arilo y R11; o pudiendo estar R9 y R10 unidos para formar un enlace, siendo el citado enlace alquileno C2-6; R11 y R12 se seleccionan cada uno independientemente de hidrógeno o alquilo C1-6; o cuando forman un resto NR11R12, R11 y R12 pueden estar también unidos para formar un enlace, siendo el citado enlace alquileno C2-6; p es 0, 1 o 2; en la que: arilo se define como un carbociclo aromático de 6 a 14 miembros, opcionalmente sustituido adicionalmente con R11, halo, OR11, NR11R12, NR11CO2R12, CO2R11, NR11SO2R12, CN, haloalquilo, O(haloalquilo), S(O)pR11, OC(O)R11, SO2NR11R12, C(O)NR11R12; heterociclo aromático se define como un anillo de 5 a 7 miembros que contiene de 1 a 3 heteroátomos, seleccionado cada uno independientemente de O, S y N, estando el citado grupo heterociclo opcionalmente sustituido con OR11, NR11R12, CO2R11, NR11CO2R12, R11, halo, CN, haloalquilo, O(haloalquilo), S(O)pR11, OC(O)R11, NR11SO2R12, SO2NR11R12, C(O)NR11R12; se define heterociclo como un anillo de 3 a 8 miembros que contiene de 1 a 3 heteroátomos seleccionados cada uno independientemente de O, S y N, estando el citado anillo saturado o parcialmente saturado, estando el citado grupo heterociclo opcionalmente sustituido adicionalmente con OR11, NR11R12, CO2R11, NR11CO2R12, R11, halo, CN, haloalquilo, O(haloalquilo), S(O)pR11, OC(O)R11, NR11SO2R12, SO2NR11R12, C(O)NR11R12; o una sal, solvato o profármaco farmacéuticamente aceptable de éstos. Estos compuestos son una clase de inhibidores de IFATa. Dichos compuestos son adecuados para uso en el tratamiento de afecciones tales como trombosis, arteriosclerosis, adherencias, cicatrices dérmicas, cáncer, afecciones fibróticas, enfermedades inflamatorias y aquellas afecciones que se benefician del mantenimiento o la potenciación de los niveles de bradiquinina en el cuerpo. Se describen también compuestos intermediarios, procedimientos de preparación y su uso en la preparación de medicamentos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0020346A GB0020346D0 (en) | 2000-08-17 | 2000-08-17 | Pharmaceuticals |
| GB0027409A GB0027409D0 (en) | 2000-11-09 | 2000-11-09 | Pharmaceuticals |
| GB0029556A GB0029556D0 (en) | 2000-12-04 | 2000-12-04 | Pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035580A1 true AR035580A1 (es) | 2004-06-16 |
Family
ID=27255849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103900A AR035580A1 (es) | 2000-08-17 | 2001-08-15 | Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentos |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1311488B1 (es) |
| JP (2) | JP4119746B2 (es) |
| KR (1) | KR20030022412A (es) |
| CN (1) | CN1443173A (es) |
| AP (1) | AP1375A (es) |
| AR (1) | AR035580A1 (es) |
| AT (1) | ATE447557T1 (es) |
| AU (1) | AU2001276605A1 (es) |
| BG (1) | BG107330A (es) |
| BR (1) | BR0113289A (es) |
| CA (1) | CA2419633C (es) |
| CY (1) | CY1109693T1 (es) |
| CZ (1) | CZ2003388A3 (es) |
| DE (1) | DE60140368D1 (es) |
| DK (1) | DK1311488T3 (es) |
| DO (1) | DOP2001000233A (es) |
| EA (1) | EA005532B1 (es) |
| EE (1) | EE200300070A (es) |
| ES (1) | ES2334101T3 (es) |
| HR (1) | HRP20030103A2 (es) |
| HU (1) | HUP0303763A3 (es) |
| IL (1) | IL153225A0 (es) |
| IS (1) | IS6638A (es) |
| MA (1) | MA26940A1 (es) |
| MX (1) | MXPA03001425A (es) |
| NO (1) | NO20030706L (es) |
| NZ (1) | NZ522823A (es) |
| OA (1) | OA12362A (es) |
| PA (1) | PA8525401A1 (es) |
| PE (1) | PE20020352A1 (es) |
| PL (1) | PL361054A1 (es) |
| PT (1) | PT1311488E (es) |
| SI (1) | SI1311488T1 (es) |
| SK (1) | SK1732003A3 (es) |
| SV (1) | SV2002000602A (es) |
| TN (1) | TNSN01126A1 (es) |
| UY (1) | UY26889A1 (es) |
| WO (1) | WO2002014285A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0103272D0 (sv) | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
| US6713496B2 (en) | 2002-01-22 | 2004-03-30 | Pfizer Inc | 3-(imidazolyl)-2-alkoxypropanoic acids |
| AP2004003084A0 (en) * | 2002-01-22 | 2004-09-30 | Pfizer | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| BR0307033A (pt) | 2002-01-22 | 2004-12-07 | Pfizer | ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas |
| EP1618380B1 (en) * | 2003-04-29 | 2009-12-30 | Universität Zürich | N epsilon AND/OR N alpha DERIVATIZED, METAL AND ORGANIC PROTECTED L-HISTIDINE FOR COUPLING TO BIOMOLECULES FOR HIGHLY EFFICIENT LABELING WITH (M(OH2)3(CO)3)+ BY FAC COORDINATION |
| SE0302853D0 (sv) * | 2003-10-29 | 2003-10-29 | Astrazeneca Ab | Chemical compounds |
| ZA200603165B (en) * | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
| CA2604912A1 (en) * | 2005-04-18 | 2006-10-26 | Bayer Schering Pharma Aktiengesellschaft | Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
| DE102005049385A1 (de) * | 2005-10-15 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Imidazolderivate als Inhibitoren von TAFIa |
| CA2671861C (en) * | 2006-12-06 | 2015-12-29 | Sanofi-Aventis | Urea and sulfamide derivatives as tafia inhibitors |
| EP2262783A2 (en) * | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
| NZ592764A (en) * | 2008-10-29 | 2012-08-31 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
| FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PL2548871T3 (pl) * | 2010-03-18 | 2017-12-29 | Daiichi Sankyo Company, Limited | Pochodne imidazolu podstawionego cykloalkilem |
| CN102884053B (zh) * | 2010-03-18 | 2016-03-02 | 第一三共株式会社 | 环丙烷甲酸衍生物 |
| EA025493B1 (ru) * | 2011-05-17 | 2016-12-30 | Акционерное Общество "Фармасинтез" | Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса |
| HUE037591T2 (hu) * | 2011-07-22 | 2018-09-28 | Cambrex Karlskoga Ab | Új eljárások 4. szénatomon szubsztituált imidazolok elõállítására |
| WO2013039202A1 (ja) * | 2011-09-15 | 2013-03-21 | 第一三共株式会社 | 新規アクリル酸誘導体 |
| SG11201509144YA (en) | 2013-06-10 | 2015-12-30 | Sanofi Sa | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI<sb>A</sb>, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS |
| EP3359528B1 (en) | 2015-10-07 | 2022-01-12 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JPWO2017170460A1 (ja) * | 2016-03-29 | 2019-02-07 | 第一三共株式会社 | 炎症性腸疾患治療剤 |
| WO2017180818A1 (en) | 2016-04-13 | 2017-10-19 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN113943255B (zh) * | 2020-07-17 | 2024-08-06 | 深圳信立泰药业股份有限公司 | 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6163661A (ja) * | 1984-09-05 | 1986-04-01 | Microbial Chem Res Found | ヒスタジン関連化合物 |
| US5993815A (en) * | 1996-11-08 | 1999-11-30 | University Of Vermont | Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI) |
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
-
2001
- 2001-08-08 BR BR0113289-0A patent/BR0113289A/pt not_active Application Discontinuation
- 2001-08-08 CZ CZ2003388A patent/CZ2003388A3/cs unknown
- 2001-08-08 AU AU2001276605A patent/AU2001276605A1/en not_active Abandoned
- 2001-08-08 IL IL15322501A patent/IL153225A0/xx unknown
- 2001-08-08 HU HU0303763A patent/HUP0303763A3/hu unknown
- 2001-08-08 KR KR10-2003-7002279A patent/KR20030022412A/ko not_active Application Discontinuation
- 2001-08-08 EE EEP200300070A patent/EE200300070A/xx unknown
- 2001-08-08 PL PL36105401A patent/PL361054A1/xx not_active Application Discontinuation
- 2001-08-08 DK DK01954264T patent/DK1311488T3/da active
- 2001-08-08 JP JP2002519428A patent/JP4119746B2/ja not_active Expired - Fee Related
- 2001-08-08 CA CA2419633A patent/CA2419633C/en not_active Expired - Fee Related
- 2001-08-08 SI SI200130950T patent/SI1311488T1/sl unknown
- 2001-08-08 PT PT01954264T patent/PT1311488E/pt unknown
- 2001-08-08 WO PCT/IB2001/001425 patent/WO2002014285A1/en not_active Application Discontinuation
- 2001-08-08 NZ NZ522823A patent/NZ522823A/en unknown
- 2001-08-08 EA EA200201239A patent/EA005532B1/ru not_active IP Right Cessation
- 2001-08-08 EP EP01954264A patent/EP1311488B1/en not_active Expired - Lifetime
- 2001-08-08 MX MXPA03001425A patent/MXPA03001425A/es active IP Right Grant
- 2001-08-08 AT AT01954264T patent/ATE447557T1/de active
- 2001-08-08 DE DE60140368T patent/DE60140368D1/de not_active Expired - Lifetime
- 2001-08-08 OA OA1200300039A patent/OA12362A/fr unknown
- 2001-08-08 CN CN01813131A patent/CN1443173A/zh active Pending
- 2001-08-08 ES ES01954264T patent/ES2334101T3/es not_active Expired - Lifetime
- 2001-08-08 SK SK173-2003A patent/SK1732003A3/sk unknown
- 2001-08-14 PA PA20018525401A patent/PA8525401A1/es unknown
- 2001-08-15 AR ARP010103900A patent/AR035580A1/es unknown
- 2001-08-15 PE PE2001000815A patent/PE20020352A1/es not_active Application Discontinuation
- 2001-08-15 UY UY26889A patent/UY26889A1/es not_active Application Discontinuation
- 2001-08-16 AP APAP/P/2001/002250A patent/AP1375A/en active
- 2001-08-16 TN TNTNSN01126A patent/TNSN01126A1/fr unknown
- 2001-08-16 SV SV2001000602A patent/SV2002000602A/es unknown
- 2001-11-14 DO DO2001000233A patent/DOP2001000233A/es unknown
-
2002
- 2002-11-28 BG BG107330A patent/BG107330A/xx unknown
- 2002-11-28 IS IS6638A patent/IS6638A/is unknown
-
2003
- 2003-02-04 MA MA27025A patent/MA26940A1/fr unknown
- 2003-02-13 HR HR20030103A patent/HRP20030103A2/hr not_active Application Discontinuation
- 2003-02-14 NO NO20030706A patent/NO20030706L/no not_active Application Discontinuation
-
2008
- 2008-02-27 JP JP2008045382A patent/JP4778531B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-30 CY CY20091101349T patent/CY1109693T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035580A1 (es) | Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentos | |
| CO6220972A2 (es) | Derivados de 6-amino dihidropurin -8-ona utiles como agentes terapeuticos y/o preventivos para el tratamiento de enfermedades alergicas, virales o cancer | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| AR033499A1 (es) | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente | |
| AR030188A1 (es) | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR056876A1 (es) | Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares | |
| AR035374A1 (es) | Un derivado de fenilacetamido-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un kit que comprende dicho derivado o composicion, un metodo para tratar desordenes proliferativos celularaes asociados con una actividad quinasa dependiente de ciclo c | |
| AR086367A1 (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
| AR047466A1 (es) | Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles. | |
| ECSP066314A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR032436A1 (es) | Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro | |
| ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| BRPI0114704B8 (pt) | composto de imidazol fundido a arila ou heteroarila, suas composições farmacêuticas, bem como seu uso | |
| DE60015927D1 (en) | Phenylharnstoff und phenylthioharnstoffderivate | |
| AR070636A1 (es) | Derivados de piridina, composicion farmaceutica y uso terapeutico | |
| RU2011116160A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и y-глутамиламиногруппой и содержащие их противогрибковые средства | |
| AR060605A1 (es) | Derivados de diazepano como antagonistas del receptor ccr2 | |
| MX2007007428A (es) | Compuestos heterociclicos, antagonistas de ccr2b. | |
| AR055321A1 (es) | Compuestos de imidazopiridina uso para a fabricacion de un medicamento para el tratamiento o profilaxis de enfermedades o trastornos en los que se requiere un antagonista de una bomba de acido y composicion farmaceutica que lo comprende | |
| RU2009149210A (ru) | Ингибиторы днк-зависимой протеинкиназы (днк-пк) | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |